Purpose Of Review: The current review focuses on the preclinical development and clinical advances of natural killer (NK) cell therapeutics for hematologic malignancies and offers perspective on the unmet challenges that will direct future discovery in the field.
Recent Findings: Approaches to improve or re-direct NK cell anti-tumor functions against hematologic malignancies have included transgenic expression of chimeric antigen receptors (CARs), administration of NK cell engagers including BiKEs and TriKEs that enhance antibody-dependent cellular cytotoxicity (ADCC) by co-engaging NK cell CD16 and antigens on tumors, incorporation of a non-cleavable CD16 that results in enhanced ADCC, use of induced memory-like NK cells alone or in combination with CARs, and blockade of NK immune checkpoints to enhance NK cytotoxicity. Recently reported and ongoing clinical trials support the feasibility and safety of these approaches. NK cell-based therapeutic strategies hold great promise as cost-effective, off-the-shelf cell therapies for patients with relapsed and refractory hematologic diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11899-023-00711-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence of oral manifestations in hematological malignancy patients undergoing chemotherapy: prospective cohort study.
Med Oral Patol Oral Cir Bucal
December 2024
Med Oral Patol Oral Cir Bucal
Background: Oral manifestations are frequent in patients with hematological malignancies undergoing chemotherapy and may be directly or indirectly related to drug toxicity. Few studies have assessed the chemotherapy and oral manifestations that patients might develop. Therefore, this study aimed to evaluate the incidence of oral manifestations in patients with hematologic neoplasms during hospitalization and chemotherapy.
View Article and Find Full Text PDFDual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers.
Oncoimmunology
December 2025
Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario12 de Octubre, Madrid, Spain.
Despite recent advances in immunotherapy against B cell malignancies such as BCMA (B cell maturation antigen) and CD19-targeted treatments using soluble T cell-engaging (TCE) antibodies or chimeric antigen receptor T cells (CAR-T), there is still an important number of patients experiencing refractory/relapsed (R/R) disease. Approaches to avoid tumor-intrinsic mechanisms of resistance such as immune pressure-mediated antigen downmodulation, are being broadly investigated. These strategies include BCMA/CD19 dual-targeting therapies, which may be of particular interest to patients with B cell lymphoma and multiple myeloma, where a specific double-positive immature subpopulation is commonly associated with poor prognosis and poor response to current treatments.
View Article and Find Full Text PDFDifferentiating reactive and neoplastic gamma-delta (γδ) T-cell expansions in the peripheral blood and bone marrow.
Cytometry B Clin Cytom
December 2024
Department of Pathology, Northwestern University Feinberg School of Medicine & Northwestern Memorial Hospital, Chicago, Illinois, USA.
The clinical and immunophenotypic attributes of reactive γδ T-cell expansions are less well characterized than their malignant counterparts, which can pose diagnostic challenges. This study aims to investigate the characteristics and long-term clinical outcomes of reactive γδ T-cell expansions. A retrospective review was performed to identify patients with expanded γδ T-cell population (>15% of T-cells) by flow cytometry in peripheral blood and/or bone marrow specimens over a 17-year period.
View Article and Find Full Text PDFPulmonologists-level lung cancer detection based on standard blood test results and smoking status using an explainable machine learning approach.
Sci Rep
December 2024
SDU Health Informatics and Technology, The Mærsk Mc-Kinney Møller Institute, University of Southern Denmark, 5230, Odense, Denmark.
Lung cancer (LC) remains the primary cause of cancer-related mortality, largely due to late-stage diagnoses. Effective strategies for early detection are therefore of paramount importance. In recent years, machine learning (ML) has demonstrated considerable potential in healthcare by facilitating the detection of various diseases.
View Article and Find Full Text PDFIncidence and outcomes of subsequent malignancy after allogeneic hematopoietic stem cell transplantation in adult patients with severe aplastic anemia.
Blood Res
December 2024
Division of Hematology-Oncology, Hanyang University Seoul Hospital, Seoul, Republic of Korea.
Purpose: This study investigated the occurrence of subsequent malignancies (SM) in adult patients with severe aplastic anemia (SAA) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to address the lack of large-scale, long-term data on this complication.
Methods: A retrospective cohort analysis of 376 adult patients with SAA who underwent allo-HSCT between 2002 and 2021 at a single center was conducted. The incidence, risk factors, and survival impact of SM were also examined.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!